Cytosorbents Cor (CTSO)

$5.76 +0.03 (0.52%)
Market Cap 19.10M
Revenue (ttm) 37.06M
Net Income (ttm) -8.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22.13%
Debt to Equity Ratio -22.99
Volume 3,067
Avg Vol 12,402
Day's Range N/A - N/A
Shares Out 3.15M
Stochastic %K 20%
Beta 1.34
Analysts Strong Sell
Price Target $106.25

Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well...

Industry: Medical Devices
Sector: Healthcare
Phone: 732 329 8885
Fax: 732 329 8650
Address:
305 College Road East, Princeton, United States
Kenzo71
Kenzo71 Sep. 17 at 1:06 PM
$CTSO premarket volume is impressive at 2 shares!
0 · Reply
OldManLogan
OldManLogan Sep. 16 at 5:38 PM
$CTSO ATM won't cut it; the first shoe has dropped; the second shoe is a financing, CEO has actually said as much. Once that's completed, this will look interesting.
1 · Reply
hanovk68
hanovk68 Sep. 16 at 3:57 PM
$CTSO Don’t see any real catalysts to drive this share price higher prior to the November earnings call. However, if they start tapping the ATM, it’ll likely start driving the share price down.
1 · Reply
okeydokey_artichokey
okeydokey_artichokey Sep. 15 at 2:30 PM
$CTSO R/S-ing into oblivion. FDA is moribund, and therefore will Kafkaesque-sleepwalk through a fog of its own making while company attempts to claw its way out of a misplaced bet on German medical reticence. This, and general EU confounders will yield a company in R&D, marketing, and revenue stasis that will persist into next offering and subsequent R/S.
0 · Reply
danielmaia12
danielmaia12 Sep. 9 at 11:55 PM
$CTSO Margins improving >> Q2 gross margin reached 73%, up from 69% in Q1!!
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Sep. 9 at 10:10 PM
$CTSO CEO purchased 200,000 shares at $0.35 for a total of $70,000. Chan Phillip P. now owns 1,944,432 shares. https://ceo-buys.com
1 · Reply
FilingTracker
FilingTracker Sep. 9 at 8:09 PM
$CTSO CEO purchase: https://filingtracker.ai/filing/1175151/0001104659-26-106308?doc=tm2625061-1_4seq1.xml
0 · Reply
hanovk68
hanovk68 Sep. 9 at 2:36 PM
$CTSO I firmly believe that the only successful investment strategy for CTSO during the remainder of the calendar year involves selling short. However, the current low number of outstanding shares (approximately 3 million) will make it difficult to access shares to sell short. However, if the Company issues and sells new shares to raise capital, accessing shares to short should become easier. Time will tell.
0 · Reply
TwongStocks
TwongStocks Sep. 8 at 8:09 PM
Today's reverse split results. 3 of 8 closed green today. Part 1 of 2: $AIXI 1 for 7 Previous close $0.4715, $3.3005 split-adjusted Today's high $3.45 (premarket) Today's close $3.26 🔴Down 1.23% $BRTX 1 for 20 Previous close $0.1480, $2.96 split-adjusted Today's high $3.23 Today's close $2.8028 🔴Down 5.31% $CTSO 1 for 20 Previous close $0.3501, $7.002 split-adjusted Today's high $7.44 Today's close $6.85 🔴Down 2.17% $GTBP 1 for 25 Previous close $0.2410, $6.025 split-adjusted Today's high $5.95 Today's close $5.2395 🔴Down 13.04%
1 · Reply
TwongStocks
TwongStocks Sep. 8 at 11:34 AM
$AIXI $BRTX $CTSO $GTBP $LRHC Are among the nine NASDAQ stocks with reverse splits today. Full details in quoted post. Trading will resume at 9:00am ET with the RS in effect.
0 · Reply
Latest News on CTSO
Cytosorbents Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 14, 2026, 11:30 AM EDT - 3 days ago

Cytosorbents Transcript: H.C. Wainwright 28th Annual Global Investment Conference

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026, 7:00 AM EDT - 7 days ago

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

CytoSorbents trading halted, news pending

2026-09-04T23:55:31.000Z - 12 days ago

CytoSorbents trading halted, news pending

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Sep 4, 2026, 9:09 AM EDT - 13 days ago

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

CytoSorbents announces 1-for-20 reverse stock split

2026-09-03T11:05:09.000Z - 14 days ago

CytoSorbents announces 1-for-20 reverse stock split

CytoSorbents Announces Reverse Stock Split

Sep 3, 2026, 7:00 AM EDT - 14 days ago

CytoSorbents Announces Reverse Stock Split

CytoSorbents announces real-world data using CytoSorb

2026-09-02T11:46:03.000Z - 15 days ago

CytoSorbents announces real-world data using CytoSorb

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

Sep 2, 2026, 7:28 AM EDT - 15 days ago

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

Cytosorbents Transcript: AGM 2026

Aug 13, 2026, 10:00 AM EDT - 5 weeks ago

Cytosorbents Transcript: AGM 2026

Cytosorbents Slides: Investor presentation

Aug 11, 2026, 8:00 AM EDT - 5 weeks ago

Cytosorbents Slides: Investor presentation

Cytosorbents Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Cytosorbents Earnings Call Transcript: Q2 2026

Cytosorbents Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Cytosorbents Quarterly report: Q2 2026

Cytosorbents Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Cytosorbents Earnings release: Q2 2026

Cytosorbents Slides: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Cytosorbents Slides: Q2 2026

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Aug 6, 2026, 4:25 PM EDT - 6 weeks ago

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

Jul 20, 2026, 7:00 AM EDT - 1 month ago

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

Cytosorbents Proxy statement: Proxy filing

Jun 25, 2026, 8:00 AM EDT - 2 months ago

Cytosorbents Proxy statement: Proxy filing

Cytosorbents Proxy statement: Proxy filing

Jun 25, 2026, 8:00 AM EDT - 2 months ago

Cytosorbents Proxy statement: Proxy filing

Cytosorbents Transcript: Life Sciences Virtual Investor Forum

Jun 24, 2026, 11:30 AM EDT - 2 months ago

Cytosorbents Transcript: Life Sciences Virtual Investor Forum

Cytosorbents Slides: Life Sciences Virtual Investor Forum

Jun 24, 2026, 11:30 AM EDT - 2 months ago

Cytosorbents Slides: Life Sciences Virtual Investor Forum

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

Jun 18, 2026, 8:46 AM EDT - 3 months ago

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

Cytosorbents Proxy statement: Proxy filing

Jun 11, 2026, 8:00 AM EDT - 3 months ago

Cytosorbents Proxy statement: Proxy filing

CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year

2026-05-13T21:05:29.000Z - 4 months ago

CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year

Cytosorbents Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 4 months ago

Cytosorbents Earnings Call Transcript: Q1 2026

Cytosorbents Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 4 months ago

Cytosorbents Earnings release: Q1 2026

Cytosorbents Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 4 months ago

Cytosorbents Quarterly report: Q1 2026

Cytosorbents Slides: Q1 2026

May 13, 2026, 4:30 PM EDT - 4 months ago

Cytosorbents Slides: Q1 2026

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

May 13, 2026, 4:00 PM EDT - 4 months ago

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights

Apr 30, 2026, 7:00 AM EDT - 4 months ago

CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights

Cytosorbents Slides: Investor presentation

Apr 1, 2026, 8:00 AM EDT - 5 months ago

Cytosorbents Slides: Investor presentation

Cytosorbents Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Cytosorbents Earnings Call Transcript: Q4 2025

Cytosorbents Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Cytosorbents Annual report: Q4 2025

Cytosorbents Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Cytosorbents Earnings release: Q4 2025

Cytosorbents Slides: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Cytosorbents Slides: Q4 2025

CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year

2026-03-25T20:11:40.000Z - 5 months ago

CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year

CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 25, 2026, 4:05 PM EDT - 5 months ago

CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026

Mar 19, 2026, 9:44 AM EDT - 6 months ago

CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026

CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 5, 2026, 7:00 AM EST - 6 months ago

CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

CytoSorbents sees Q4 revenue $9.2M, consensus $9.85M

2026-01-12T12:10:48.000Z - 8 months ago

CytoSorbents sees Q4 revenue $9.2M, consensus $9.85M

CytoSorbents sees FY25 revenue $37M, consensus $37.67M

2026-01-12T12:10:19.000Z - 8 months ago

CytoSorbents sees FY25 revenue $37M, consensus $37.67M

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update

Jan 12, 2026, 7:00 AM EST - 8 months ago

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update

Cytosorbents Transcript: Fireside Chat

Dec 15, 2025, 11:00 AM EST - 9 months ago

Cytosorbents Transcript: Fireside Chat

CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

Dec 10, 2025, 7:00 AM EST - 9 months ago

CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

Cytosorbents Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 7:30 AM EST - 10 months ago

Cytosorbents Transcript: Jefferies London Healthcare Conference 2025

Cytosorbents Slides: FY 2025

Nov 18, 2025, 7:30 AM EST - 10 months ago

Cytosorbents Slides: FY 2025

Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

Nov 17, 2025, 5:42 PM EST - 10 months ago

Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

CytoSorbents price target lowered to 75c from $1 at H.C. Wainwright

2025-11-14T11:20:53.000Z - 10 months ago

CytoSorbents price target lowered to 75c from $1 at H.C. Wainwright

Cytosorbents Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Cytosorbents Earnings Call Transcript: Q3 2025

Cytosorbents Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Cytosorbents Earnings release: Q3 2025

Cytosorbents Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Cytosorbents Quarterly report: Q3 2025

Cytosorbents Slides: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Cytosorbents Slides: Q3 2025

CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)

2025-11-13T21:21:57.000Z - 10 months ago

CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)

CytoSorbents implemented workforce and cost reduction program

2025-11-13T21:21:01.000Z - 10 months ago

CytoSorbents implemented workforce and cost reduction program

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:05 PM EST - 10 months ago

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

Nov 11, 2025, 7:00 AM EST - 10 months ago

CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 30, 2025, 7:00 AM EDT - 10 months ago

CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer

Oct 28, 2025, 7:00 AM EDT - 10 months ago

In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

Sep 29, 2025, 7:00 AM EDT - 11 months ago

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

CytoSorbents provides DrugSorb-ATR regulatory update

2025-09-16T11:10:14.000Z - 1 year ago

CytoSorbents provides DrugSorb-ATR regulatory update

CytoSorbents Provides DrugSorb-ATR Regulatory Update

Sep 16, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Provides DrugSorb-ATR Regulatory Update

Cytosorbents Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:30 AM EDT - 1 year ago

Cytosorbents Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Cytosorbents Slides: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:30 AM EDT - 1 year ago

Cytosorbents Slides: H.C. Wainwright 27th Annual Global Investment Conference

CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day

Sep 8, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day

CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CytoSorbents provides update of its appeal with FDA regarding DrugSorb-ATR

2025-08-20T11:10:17.000Z - 1 year ago

CytoSorbents provides update of its appeal with FDA regarding DrugSorb-ATR

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

Aug 20, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

Cytosorbents Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings Call Transcript: Q2 2025

Cytosorbents Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Quarterly report: Q2 2025

Cytosorbents Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings release: Q2 2025

CytoSorbents reports Q 2 adjusted EPS (5c) vs. (5c) last year

2025-08-07T20:05:43.000Z - 1 year ago

CytoSorbents reports Q 2 adjusted EPS (5c) vs. (5c) last year

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:00 PM EDT - 1 year ago

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

CytoSorbents Leads a New Era in Sepsis Treatment

Jul 31, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Leads a New Era in Sepsis Treatment

CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 29, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

CytoSorbents provides FDA, Health Canada regulatory update for DrugSorb-ATR

2025-07-02T11:05:43.000Z - 1 year ago

CytoSorbents provides FDA, Health Canada regulatory update for DrugSorb-ATR

CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

Jul 2, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

CytoSorbents files appeal with FDA for review of request for DrugSorb-ATR

2025-06-24T11:11:15.000Z - 1 year ago

CytoSorbents files appeal with FDA for review of request for DrugSorb-ATR

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

Jun 24, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

Cytosorbents Slides: Investor Presentation

Jun 6, 2025, 7:00 AM EDT - 1 year ago

Cytosorbents Slides: Investor Presentation

Cytosorbents Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 9:20 AM EDT - 1 year ago

Cytosorbents Transcript: Jefferies Global Healthcare Conference 2025

CytoSorbents to Participate at the Jefferies Global Healthcare Conference

May 29, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents to Participate at the Jefferies Global Healthcare Conference

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

May 22, 2025, 9:27 AM EDT - 1 year ago

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

Cytosorbents Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings Call Transcript: Q1 2025

Cytosorbents Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Quarterly report: Q1 2025

Cytosorbents Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings release: Q1 2025

Cytosorbents Slides: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Slides: Q1 2025

CytoSorbents reports Q1 EPS (2c) vs. (11c) last year

2025-05-14T20:05:50.000Z - 1 year ago

CytoSorbents reports Q1 EPS (2c) vs. (11c) last year

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 4:01 PM EDT - 1 year ago

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

CytoSorbents: FDA issues denial letter for De Novo Request for DrugSorb-ATR

2025-05-01T20:52:28.000Z - 1 year ago

CytoSorbents: FDA issues denial letter for De Novo Request for DrugSorb-ATR

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

May 1, 2025, 4:15 PM EDT - 1 year ago

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

Apr 29, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

Cytosorbents Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Cytosorbents Proxy statement: Proxy Filing

Cytosorbents Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Cytosorbents Proxy statement: Proxy Filing

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

Apr 21, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

Apr 17, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

Apr 14, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants

Apr 4, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants

Cytosorbents Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings Call Transcript: Q4 2024

Cytosorbents Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings release: Q4 2024

Cytosorbents Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Annual report: Q4 2024

Cytosorbents Slides: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Slides: Q4 2024

CytoSorbents reports Q4 adjusted EPS (3c) vs. (17c) last year

2025-03-31T20:20:34.000Z - 1 year ago

CytoSorbents reports Q4 adjusted EPS (3c) vs. (17c) last year

CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 31, 2025, 4:15 PM EDT - 1 year ago

CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

Mar 21, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

CytoSorbents postpones earnings release to allow time for annual audit

2025-03-04T12:13:57.000Z - 1 year ago

CytoSorbents postpones earnings release to allow time for annual audit

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

Mar 4, 2025, 7:00 AM EST - 1 year ago

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

Jan 3, 2025, 7:00 AM EST - 1 year ago

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Dec 12, 2024, 7:00 AM EST - 1 year ago

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Cytosorbents Slides: Investor Presentation

Dec 12, 2024, 7:00 AM EST - 1 year ago

Cytosorbents Slides: Investor Presentation

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

Nov 11, 2024, 7:30 AM EST - 1 year ago

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

Cytosorbents Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cytosorbents Earnings Call Transcript: Q3 2024

Cytosorbents Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cytosorbents Quarterly report: Q3 2024

Cytosorbents Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cytosorbents Earnings release: Q3 2024

Cytosorbents Slides: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cytosorbents Slides: Q3 2024

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

Oct 1, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

Cytosorbents Registration statement: Registration Filing

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Cytosorbents Registration statement: Registration Filing

Cytosorbents Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Cytosorbents Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

Aug 27, 2024, 7:00 AM EDT - 2 years ago

CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 16, 2024, 4:05 PM EDT - 2 years ago

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytosorbents Earnings Call Transcript: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Earnings Call Transcript: Q2 2024

Cytosorbents Quarterly report: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Quarterly report: Q2 2024

Cytosorbents Earnings release: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Earnings release: Q2 2024

Cytosorbents Slides: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Slides: Q2 2024

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

Aug 13, 2024, 4:19 PM EDT - 2 years ago

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

Aug 13, 2024, 4:18 PM EDT - 2 years ago

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

Aug 7, 2024, 7:00 AM EDT - 2 years ago

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

Kenzo71
Kenzo71 Sep. 17 at 1:06 PM
$CTSO premarket volume is impressive at 2 shares!
0 · Reply
OldManLogan
OldManLogan Sep. 16 at 5:38 PM
$CTSO ATM won't cut it; the first shoe has dropped; the second shoe is a financing, CEO has actually said as much. Once that's completed, this will look interesting.
1 · Reply
hanovk68
hanovk68 Sep. 16 at 3:57 PM
$CTSO Don’t see any real catalysts to drive this share price higher prior to the November earnings call. However, if they start tapping the ATM, it’ll likely start driving the share price down.
1 · Reply
okeydokey_artichokey
okeydokey_artichokey Sep. 15 at 2:30 PM
$CTSO R/S-ing into oblivion. FDA is moribund, and therefore will Kafkaesque-sleepwalk through a fog of its own making while company attempts to claw its way out of a misplaced bet on German medical reticence. This, and general EU confounders will yield a company in R&D, marketing, and revenue stasis that will persist into next offering and subsequent R/S.
0 · Reply
danielmaia12
danielmaia12 Sep. 9 at 11:55 PM
$CTSO Margins improving >> Q2 gross margin reached 73%, up from 69% in Q1!!
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Sep. 9 at 10:10 PM
$CTSO CEO purchased 200,000 shares at $0.35 for a total of $70,000. Chan Phillip P. now owns 1,944,432 shares. https://ceo-buys.com
1 · Reply
FilingTracker
FilingTracker Sep. 9 at 8:09 PM
$CTSO CEO purchase: https://filingtracker.ai/filing/1175151/0001104659-26-106308?doc=tm2625061-1_4seq1.xml
0 · Reply
hanovk68
hanovk68 Sep. 9 at 2:36 PM
$CTSO I firmly believe that the only successful investment strategy for CTSO during the remainder of the calendar year involves selling short. However, the current low number of outstanding shares (approximately 3 million) will make it difficult to access shares to sell short. However, if the Company issues and sells new shares to raise capital, accessing shares to short should become easier. Time will tell.
0 · Reply
TwongStocks
TwongStocks Sep. 8 at 8:09 PM
Today's reverse split results. 3 of 8 closed green today. Part 1 of 2: $AIXI 1 for 7 Previous close $0.4715, $3.3005 split-adjusted Today's high $3.45 (premarket) Today's close $3.26 🔴Down 1.23% $BRTX 1 for 20 Previous close $0.1480, $2.96 split-adjusted Today's high $3.23 Today's close $2.8028 🔴Down 5.31% $CTSO 1 for 20 Previous close $0.3501, $7.002 split-adjusted Today's high $7.44 Today's close $6.85 🔴Down 2.17% $GTBP 1 for 25 Previous close $0.2410, $6.025 split-adjusted Today's high $5.95 Today's close $5.2395 🔴Down 13.04%
1 · Reply
TwongStocks
TwongStocks Sep. 8 at 11:34 AM
$AIXI $BRTX $CTSO $GTBP $LRHC Are among the nine NASDAQ stocks with reverse splits today. Full details in quoted post. Trading will resume at 9:00am ET with the RS in effect.
0 · Reply
ijod
ijod Sep. 6 at 8:03 PM
$CTSO
1 · Reply
TwongStocks
TwongStocks Sep. 4 at 8:09 PM
Nine NASDAQ stocks with reverse splits on Tuesday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Tuesday morning. I'll have to split this into two parts. Part 1 of 2: $AIXI 1 for 7. They do not have any recent SEC filings that confirm the current number of ADS outstanding. Unable to provide estimated post-RS share count without up to date data. $BRTX 1 for 20. Will reduce outstanding shares from approx 27.62m to approx 1.38m. $CTSO 1 for 20. Will reduce outstanding shares from approx 63.02m to approx 3.15m. $GTBP 1 for 25. Will reduce outstanding shares from approx 45.11m to approx 1.80m. $LRHC 1 for 6. Will reduce outstanding shares from approx 3.4m to approx 569k.
0 · Reply
newsfile_corp
newsfile_corp Sep. 4 at 1:10 PM
https://nfne.ws/312850 $CTSO #Energy #Banking #FinancialServices #NASDAQ #Investing
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann Sep. 3 at 8:11 PM
$CTSO ouch, who would buy this after yet another reverse? Seems like all they can sell is stock.
1 · Reply
TwongStocks
TwongStocks Sep. 3 at 7:28 PM
$CTSO Equity Corporate Actions Alert #2026 - 638 Information Regarding the Reverse Stock Split and CUSIP Number Change for Cytosorbents Corporation (CTSO) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2026-638 Cytosorbents Corporation (CTSO) will effect a one-for-twenty (1-20) reverse split of its Common Stock. The reverse stock split will become effective on Tuesday, September 8, 2026. In conjunction with the reverse split, the CUSIP number will change to 23283X305.
0 · Reply
ZacksSCR
ZacksSCR Sep. 3 at 1:32 PM
$CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor https://buff.ly/oY5WUeM
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 3 at 12:33 PM
$CTSO (-10.5% pre) CytoSorbents Announces Reverse Stock Split https://ooc.bz/l/113157
0 · Reply
Kenzo71
Kenzo71 Sep. 3 at 12:26 PM
$CTSO Now that the 20:1 reverse stock split has been announced to take place on Sept 8, I anticipate we we will see a forthcoming announcement prior to the end of the calendar year announcing a dilutive issuance of additional shares to provide the Company with additional working capital. In addition, I expect short sellers will aggressively move in after the reverse split given their anticipation of a future dilutive financing round. Hope I’m wrong, but I doubt it.
0 · Reply
TwongStocks
TwongStocks Sep. 3 at 11:12 AM
$CTSO CytoSorbents Announces 1 for 20 Reverse Stock Split https://www.prnewswire.com/news-releases/cytosorbents-announces-reverse-stock-split-302868315.html Expected to Become Effective and Trade on Split-Adjusted Basis at the Market Open on September 8, 2026.
0 · Reply
Ron_Burn
Ron_Burn Sep. 2 at 6:34 PM
$CTSO fluff news, someone is unloading its bag
0 · Reply
prismmarketview
prismmarketview Sep. 2 at 6:21 PM
$CTSO presented new real-world data at ESC 2026 showing intraoperative CytoSorb reduced severe bleeding from 34.5% to 21.8% in urgent CABG patients on ticagrelor, and submitted an expanded dataset supporting a new DrugSorb-ATR De Novo application. https://prismmarketview.com/companies/cytosorbents-corporation/#news
0 · Reply
RTPRwire
RTPRwire Sep. 2 at 6:03 PM
$CTSO is seeing a strong reaction on clinical trial results following a PR Newswire release. CytoSorbents announces real-world data showing 37% reduction in severe bleeding with CytoSorb in CABG patients on ticagrelor, supporting FDA De Novo submission for DrugSorb-ATR. RTPR pushed this release out to users at 7:29:18 AM ET
0 · Reply